



Dr Thomas Joudinaud
CEO Ceres Brain Therapeutics
ICM, Hôpital La Pitié-Salpêtrière
47 Bd de l'Hôpital, 75013 Paris
France

Paris January 30th, 2025

To the ACD Community,

Dear All,

As you know, Ceres Brain Therapeutics is developing a medicine that brings creatine to brain neurons. We have demonstrated the potential efficacy of CBT101 in Creatine Transporter Deficiency patients through many studies in animals and, these results were published in peer-reviewed journals. As a reminder, CBT101 is a nasal spray that must be administered daily in each nostril of patients.

As explained in the last ACD meeting in Salt Lake City on June 30th, 2024, we have transformed the molecule into CBT101, a pharmaceutical product that can be industrially produced in compliance with all the pharmaceutical industry regulations. We have also conducted the necessary safety studies required by the authorities to grant the authorization to test this medicine in human, first in healthy volunteers.

Today, I am pleased along with Henri Bénech, Ceres' Chief Operating Officer, and our entire team, to inform you that the EMA and the French regulatory authorities gave us the authorization to test CBT101 in Humans.

The next step is therefore to test CBT101 in healthy volunteers for up to 14 days to demonstrate its safety which we refer to as Phase 1. In parallel, we will conduct long term toxicology studies, with two objectives: (1) ensure that there is no harm to treat for a long period of time, (2) define the best dosage for further tests in patients.

These studies will be conducted in 2025 thanks to the recent funding round we successfully closed, and I would like to deeply thank our historical investors for their support, and the commitment of Aurélien Chaufour from the Anjac group.

Then, the obvious next step will be to start clinical trials in patients, which, if all goes well, will begin in the second half of 2026. As you know, there are still many things to address before



starting those trials, including securing funding. All team members are focused on these next steps, and I would like to extend my gratitude to the medical doctors, advisors and researchers working with us to define the relevant methodology for the trials.

We are increasingly confident that our medicine could improve your children's symptoms while being easy to administrate daily via the CBT101 nasal spray.

At ceres, we all main committed to you and your children, and we look forward to seeing you at the next annual meeting.

Sincerely,

Thomas